Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Saved in:
| Title: | Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. |
|---|---|
| Authors: | Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. I.N.T. IRCCS Fondazione 'G. Pascale', Napoli, Italy. p.ascierto@istitutotumori.na.it., Casula M; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, 07100, Sassari, Italy., Bulgarelli J; Immunotherapy, Cell Therapy Unit and Biobank Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Pisano M; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, 07100, Sassari, Italy., Piccinini C; Immunotherapy, Cell Therapy Unit and Biobank Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Piccin L; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Cossu A; Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy., Mandalà M; University of Perugia, Perugia, Italy.; Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy., Ferrucci PF; Biotherapy of Tumors Unit, Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Guidoboni M; Immunotherapy, Cell Therapy Unit and Biobank Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 -, Warsaw, Poland., Ferraresi V; Department of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Arance A; Department of Medical Oncology, Hospital Clínic Barcelona, 08036, Barcelona, Spain., Guida M; Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori 'Giovanni Paolo II', Bari, Italy., Maiello E; Oncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy., Gogas H; First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Richtig E; Department of Dermatology, Medical University of Graz, Graz, Austria., Fierro MT; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy., Lebbe C; Dermato-Oncology and CIC AP-HP Hôpital Saint Louis,Cancer Institute APHP. Nord-Université Paris Cite F-75010, Paris, INSERM U976, France., Helgadottir H; Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden., Queirolo P; Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Division of melanoma Sarcoma and Rare Tumors, IRCCS European Institute of Oncology, Milan, Italy., Spagnolo F; Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Tucci M; Department of Interdisciplinary Medicine, Oncology Unit, University of Bari 'Aldo Moro', Bari, Italy., Del Vecchio M; Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cao MG; Department of Medical Oncology, University Hospital Dexeus, Barcelona, Spain., Minisini AM; Academic Hospital 'Santa Maria della Misericordia', Udine, Italy., De Placido S; Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy., Sanmamed MF; Department of Interdisciplinary Medicine, Oncology Unit, University of Bari 'Aldo Moro', Bari, Italy., Mallardo D; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. I.N.T. IRCCS Fondazione 'G. Pascale', Napoli, Italy., Paone M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. I.N.T. IRCCS Fondazione 'G. Pascale', Napoli, Italy., Vitale MG; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. I.N.T. IRCCS Fondazione 'G. Pascale', Napoli, Italy., Melero I; Department of Immunology and Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Grimaldi AM; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics. I.N.T. IRCCS Fondazione 'G. Pascale', Napoli, Italy.; Medical Oncology Unit, AORN San Pio, Benevento, Italy., Giannarelli D; Fondazione Policlinico Universitario A. Gemelli, IRCCS - Facility of Epidemiology and Biostatistics, Rome, Italy., Dummer R; Department of Dermatology, University and University Hospital Zurich, Zurich, Switzerland., Sileni VC; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Palmieri G; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, 07100, Sassari, Italy. |
| Source: | Nature communications [Nat Commun] 2024 Jan 02; Vol. 15 (1), pp. 146. Date of Electronic Publication: 2024 Jan 02. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
